Clinical trial
Neoadjuvant/Adjuvant Pembrolizumab Plus Chemotherapy
NCT05383716
Study timeline
Study start (actual)2022-07-01Date precision: day
Registry last updated2024-04-23
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Non Small Cell Lung Cancerunresolved
Neoadjuvant Therapyunresolved
Immune Checkpoint Inhibitorunresolved
Interventions
PembrolizumabDRUG · verified · RxNorm: pembrolizumab
Sponsors & collaborators
Peking Union Medical College Hospitallead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05383716 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.